Enanta Pharmaceuticals Inc (ENTA)

22.10
0.34 1.50
NASDAQ : Health Care
Prev Close 22.44
Open 22.34
Day Low/High 22.03 / 22.62
52 Wk Low/High 16.75 / 43.08
Volume 118.92K
Avg Volume 276.80K
Exchange NASDAQ
Shares Outstanding 19.04M
Market Cap 426.02M
EPS 4.20
P/E Ratio 14.82
Div & Yield N.A. (N.A)

Latest News

Enanta Announces The U.S. Food And Drug Administration Has Approved AbbVie's New, Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus

Enanta Announces The U.S. Food And Drug Administration Has Approved AbbVie's New, Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C Virus

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis

Enanta Pharmaceuticals To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals To Host Conference Call On August 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Commit To Buy Enanta Pharmaceuticals At $19, Earn 12.7% Annualized Using Options

Commit To Buy Enanta Pharmaceuticals At $19, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of Enanta Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $23.72/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus

Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated...

Enanta Pharmaceuticals is Now Oversold (ENTA)

Enanta Pharmaceuticals is Now Oversold (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Trade-Ideas LLC identified Enanta Pharmaceuticals (ENTA) as a strong on high relative volume candidate

ENTA: Insiders vs. Shorts

ENTA: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Enanta Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 11.09 "days to cover" versus the median component at 6.16.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Oversold Conditions For Enanta Pharmaceuticals (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals To Host Conference Call On May 9 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals To Host Conference Call On May 9 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals To Present At The Deutsche Bank 41st Annual Healthcare Conference Presentation To Be Webcast On May 4, 2016 At 8:00 A.M. ET

Enanta Pharmaceuticals To Present At The Deutsche Bank 41st Annual Healthcare Conference Presentation To Be Webcast On May 4, 2016 At 8:00 A.M. ET

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces U.S. FDA Has Approved AbbVie's Supplemental New Drug Application For Use Of VIEKIRA PAK® Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis

Enanta Announces U.S. FDA Has Approved AbbVie's Supplemental New Drug Application For Use Of VIEKIRA PAK® Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that the U.

AbbVie Receives U.S. FDA Approval Of Supplemental New Drug Application For VIEKIRA PAK® (ombitasvir, Paritaprevir, And Ritonavir Tablets; Dasabuvir Tablets) Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis

AbbVie Receives U.S. FDA Approval Of Supplemental New Drug Application For VIEKIRA PAK® (ombitasvir, Paritaprevir, And Ritonavir Tablets; Dasabuvir Tablets) Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis

- Approval supported by TURQUOISE-III study showing 100 percent SVR12 (N=60/60) in chronic hepatitis C virus (HCV) infected genotype 1b patients with compensated cirrhosis (Child-Pugh A)

Enanta Announces New Data From AbbVie's SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus

Enanta Announces New Data From AbbVie's SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases today announced that with eight weeks...

Enanta Announces That AbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals

Enanta Announces That AbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that in AbbVie's...

AbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals

AbbVie's Investigational, Pan-Genotypic Regimen Of ABT-493 And ABT-530 Shows High SVR Rates In Genotype 1 Hepatitis C Patients Who Failed Previous Therapy With Direct-Acting Antivirals

- 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis

AbbVie Announces Real-World Data With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) And EXVIERA® (dasabuvir Tablets) From Large German Hepatitis C-Registry

AbbVie Announces Real-World Data With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) And EXVIERA® (dasabuvir Tablets) From Large German Hepatitis C-Registry

- VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1)

Enanta Announces High SVR Rates With AbbVie's VIEKIRAX® + EXVIERA® Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients

Enanta Announces High SVR Rates With AbbVie's VIEKIRAX® + EXVIERA® Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today data showing that...

AbbVie Announces High SVR Rates With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients

AbbVie Announces High SVR Rates With VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients

- 100 percent of genotype 1b patients, who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVR48 in a post-hoc analysis no matter whether baseline NS5A RAVs were present(1)

Enanta Pharmaceuticals Announces HCV Data Presentations At The International Liver Congress™ 2016

Enanta Pharmaceuticals Announces HCV Data Presentations At The International Liver Congress™ 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that several...

AbbVie To Present Data On VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) And EXVIERA® (dasabuvir Tablets) And Investigational, Pan-Genotypic Regimen At The International Liver Congress™ 2016

AbbVie To Present Data On VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) And EXVIERA® (dasabuvir Tablets) And Investigational, Pan-Genotypic Regimen At The International Liver Congress™ 2016

- Real-world and Phase 3/3b clinical trial data to be presented on VIEKIRAX® and EXVIERA® in genotype 1 and genotype 4 chronic hepatitis C virus infected patients

First Week of May 20th Options Trading For Enanta Pharmaceuticals (ENTA)

First Week of May 20th Options Trading For Enanta Pharmaceuticals (ENTA)

Investors in Enanta Pharmaceuticals, Inc. saw new options become available this week, for the May 20th expiration.

Enanta Pharmaceuticals To Present At The Barclays Global Healthcare Conference

Enanta Pharmaceuticals To Present At The Barclays Global Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Announces CHMP Positive Opinion For AbbVie's VIEKIRAX® + EXVIERA® Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis

Enanta Pharmaceuticals Announces CHMP Positive Opinion For AbbVie's VIEKIRAX® + EXVIERA® Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that the Committee...

AbbVie Receives CHMP Positive Opinion For VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis (Child-Pugh A) In Europe

AbbVie Receives CHMP Positive Opinion For VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis (Child-Pugh A) In Europe

- EU label expansion supported by high cure rates shown in TURQUOISE-III study, a dedicated Phase 3b study of VIEKIRAX + EXVIERA without ribavirin for 12 weeks

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

Stocks with insider trader activity include ENTA, EBIO and PSEC